TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03691857

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound algorithm (EMERALD-US)
Description: Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
Study: NCT03651505

Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as a part of this DMP

Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as a part of this DMP
Study: NCT04522817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS119
Description: Peripheral blood derived autologous CD34+ cells
Study: NCT01192763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study: NCT02679144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
Study: NCT04493424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study: NCT02551094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colchicine
Description: 0.5 mg tablet taken once a day
Study: NCT01192763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT02551094

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colchicine placebo
Description: sugar pill manufactured to mimic colchicine 0.5 mg tablet
Study: NCT02920528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: sub-dissociative ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: sub-dissociative ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT02079116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 grams of fat plus water solution
Description: A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 60 grams of fat plus water solution
Description: A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study: NCT01192763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT03092986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
Study: NCT04318223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
Study: NCT02186834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor orally as outlined in the study treatment arm.
Study: NCT03092986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three dimensional conformal radiotherapy
Description: three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: three dimensional conformal radiotherapy
Description: three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
Study: NCT00093197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 0.05 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 1.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01321944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Smoker Outreach Program
Description: Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs.
Study: NCT02964559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01791049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03939767

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
Study: NCT03453619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: APL-2 administered as a daily subcutaneous infusion for 48 weeks
Study: NCT04517695

Intervention type: DEVICE
Intervention: BVA-100
Description: The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.

Intervention type: DEVICE
Intervention: BVA-100
Description: The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.

Intervention type: DEVICE
Intervention: Transpulmonary Thermodilution (TPTD)
Description: TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.

Intervention type: DEVICE
Intervention: Transpulmonary Thermodilution (TPTD)
Description: TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.

Intervention type: DEVICE
Intervention: Sublingual Microcirculation
Description: With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.

Intervention type: DEVICE
Intervention: Sublingual Microcirculation
Description: With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
Study: NCT02290691

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza Vaccine
Study: NCT03695614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
Study: NCT00336284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring
Description: Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.

Intervention type: OTHER
Group type: OTHER
Intervention: In-Office Conventional Follow-up
Description: Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
Study: NCT02321787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound for confirmation of successful caudal block
Description: Use of ultrasound for confirmation of successful caudal block
Study: NCT02810912

Intervention type: OTHER
Intervention: the effect of surgical position
Description: Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
Study: NCT02407080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7388
Description: RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
Study: NCT03539744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral, locally available form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral, locally available form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet; oral
Study: NCT03978052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EGCG
Description: Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Healthy lifestyle recommendations
Description: Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention
Description: * Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal lifestyle intervention
Description: * Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions.
Study: NCT03017872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.
Study: NCT01299337

Intervention type: DRUG
Intervention: T3
Description: Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
Study: NCT01337843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Workbook
Description: A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management Print Materials
Description: Print materials comparable to the content within Wellness Workbook
Study: NCT01814319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 1 gr oral twice daily
Description: Probenecid 1 gram oral twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral twice daily
Study: NCT01139411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Control with Enhanced Parent Involvement

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Weight Control with Minimal Parent Involvement
Study: NCT03724383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factor Management Consult
Description: Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Classes
Description: Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Classes
Description: Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Classes
Description: Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise program
Description: The interval and resistance training program will mirror the supervised exercise.
Study: NCT01236066

Intervention type: OTHER
Intervention: Database analysis
Description: Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
Study: NCT01618045

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fermented Papaya Preparation (FPP)
Description: Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
Study: NCT04860557

Intervention type: OTHER
Intervention: cognitive skill, dual task and physical activity assessment
Description: Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.

Intervention type: OTHER
Intervention: cognitive skill, dual task and physical activity assessment
Description: Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
Study: NCT00491036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraaortic balloon pump
Description: intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
Study: NCT03892668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
Study: NCT02890303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zepto System
Description: Anterior Capsulotomy using the Zepto System.
Study: NCT02350166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: laparoscopic-assisted small-incision surgery
Study: NCT00777985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5 mg b.i.d for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure (CPAP)
Description: Daily application throughout sleep for 4 weeks
Study: NCT04689490

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Only diagnostic tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Only diagnostic tests